Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute
SAN JOSE, Calif., March 24 (Reuters) - A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.
No comments:
Post a Comment